Home
IDEAYA Biosciences

IDEAYA Biosciences Market Share Analysis for March 2026

Health > Biotechnology and Pharmaceuticals

Domainideayabio.com

Year Founded2015

Employees51 - 200

Annual Revenue$200M - $500M

IDEAYA Biosciences

IDEAYA Biosciences (including company regionals)

ideayabio.com

See more website traffic and engagement information

IDEAYA Biosciences Revenue up to March 2026 is 200M - 500M

revenue generated by IDEAYA Biosciences top domains

IDEAYA Biosciences top domains revenue over 3 years

Revenue for IDEAYA Biosciences top domains

ideayabio.com200M - 500M

See more with Sales Intelligence

Total visits to IDEAYA Biosciences's top domains

Understand IDEAYA Biosciences market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

ideayabio.com12.3K

See more with Sales Intelligence

Avg. visit duration in IDEAYA Biosciences's top domains

Analyze IDEAYA Biosciences engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

ideayabio.com00:00:38

See more with Sales Intelligence

Avg. pageviews on IDEAYA Biosciences's top domains

See how IDEAYA Biosciences keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

ideayabio.com1.97

See more with Sales Intelligence

IDEAYA Biosciences top competitors by domain

Top similar sites in March 2026, ranked by their affinity

ideapharma.comCompany NameIDEA PharmaEmployees51 - 200HQUnited States, California, San FranciscoAnnual revenue$25M - $50MTotal visits3KHealth > Biotechnology and Pharmaceuticals

Top technologies used by IDEAYA Biosciences

These are the website technologies, by industry, used by IDEAYA Biosciences top domains

Email Services (5)

Sendgrid

Content Management System (3)

WordPress

Advertising (2)

DoubleClick

Conversion & Analytics (2)

Google Analytics

More Technologies

10

See all

News & Signals from IDEAYA Biosciences

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCompany is developing ide849-imfinzi SCLC trial.IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on ide849-imfinzi SCLC trial.

NewsCompany increased headcount by 2 on Mar 26th '26.SOUTH SAN FRANCISCO, Calif., March 27, 2026 /PRNewswire/ - IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 26, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 49,000 shares of the Company's common stock to two newly hired employees.